

1 Profiling of circulating chromosome 21-encoded microRNAs, miR-155 and
2 Let-7c, in Down Syndrome People

3
4 Jesús Manuel Pérez-Villareal^{1,2,3,¶}, Katia Aviña-Padilla^{4,¶}, Evangelina Beltrán López⁵, Alma
5 Marlene Guadrón-Llanos⁶, Esther López-Bayghen⁷, Javier Magaña-Gómez^{2,3}, Marco
6 Antonio Meraz-Ríos⁸, Alfredo Varela-Echavarría⁴, Carla Angulo-Rojo^{1*}.

7
8 ¹Laboratorio de Neurociencias, Centro de Investigación Aplicada a la Salud Pública
9 (CIASaP), Facultad de Medicina, Universidad Autónoma de Sinaloa. Culiacán, Sinaloa,
10 México.

11
12 ²Maestría en Ciencias Biomédicas, Facultad de Ciencias Químico-Biológicas, Universidad
13 Autónoma de Sinaloa. Culiacán, Sinaloa, México.

14
15 ³Laboratorio de Nutrición Molecular, Escuela de Nutrición y Gastronomía, Universidad
16 Autónoma de Sinaloa. Culiacán, Sinaloa, México.

17
18 ⁴Instituto de Neurobiología, Universidad Nacional Autónoma de México. Querétaro,
19 Querétaro, México.

20
21 ⁵Laboratorio Edificio Central, Facultad de Ciencias Químico-Biológicas, Universidad
22 Autónoma de Sinaloa. Culiacán, Sinaloa, México.

23
24 ⁶Laboratorio de Diabetes y comorbilidades, Centro de Investigación Aplicada a la Salud
25 Pública (CIASaP), Facultad de Medicina, Universidad Autónoma de Sinaloa. Culiacán,
26 Sinaloa, México.

27

28 ⁷Departamento de Toxicología, Centro de Investigación y de Estudios Avanzados del
29 Instituto Politécnico Nacional (CINVESTAV-IPN), México City, México.

30

31 ⁸Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios
32 Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), México City, México.

33

34

35 * Corresponding author

36 E-mail: carla.angulo@uas.edu.mx

37

38 [¶]These authors contributed equally to this work.

39 **Abstract**

40 Down syndrome (DS), or Trisomy 21 (Ts21), is the most common chromosomal survival
41 aneuploidy. Nevertheless, people with DS have compromised health, and the increase in
42 their life expectancy further heightens the risk of developing chronic degenerative diseases
43 such as obesity, dyslipidemias and diabetes mellitus associated with higher morbidity, and
44 mortality for cardiovascular disease from an early age. DS is also accompanied by a higher
45 risk of neurodegeneration. The extra genetic material that characterizes DS causes an
46 imbalance in the genetic dosage, including overexpression of miR-155 and Let-7c
47 miRNAs, both associated with cognitive impairment and dementia in adults. The dynamics
48 of expression of their putative target genes in the early stages of the development of DS and
49 their clinical associations, however, remain to be ascertained. This study aimed to evaluate
50 the relative expression of miR-155 and Let-7c in young and adult individuals with DS and
51 its possible association with biochemical indicators of lipid metabolism. The
52 anthropometric, clinical, biochemical, and gene expression features of miR-155 and Let-7c
53 were analyzed in a population of 52 control and 50 DS subjects divided into groups of 20
54 years of age or younger and 21 years or older. Expression changes for miR-155 were not
55 significant. Nevertheless, a negative correlation for HDL-Cholesterol concentrations and
56 miR-155 expression was identified. Notably, Let-7c was overexpressed in DS from young
57 and old ages. Overall, our results suggest that Let-7c is related from early stages to
58 cognitive impairment in DS, while a similar role of miR-155 in late stages could be
59 mediated by alterations in lipid metabolism. Further studies with both miRNAs will shed

60 light on their potential as therapeutic targets to prevent or delay cognitive impairment in

61 DS.

62 **Keywords:** *Down syndrome, obesity, dyslipidemias, miRNAs, lipid metabolism,*

63 *cholesterol.*

64 **Introduction**

65 Down syndrome (DS), or Trisomy 21, is the most common survivable chromosomal
66 aneuploidy, occurring at an approximate rate between 6 and 13 in 10,000 births (1, 2). The
67 prevalence has been increasing in recent decades as the life expectancy of people with DS
68 has expanded to 60 years (3). In addition to cognitive dysfunction, several clinical
69 symptoms have been described for the DS population, including craniofacial abnormalities,
70 gastrointestinal anomalies, congenital heart disease, childhood leukemia, and early-onset
71 Alzheimer’s disease (AD) (4). Moreover, DS individuals have an increased risk of
72 overweight, obesity, and dyslipidemias, which confer a high risk of cardiovascular disease
73 in general, ischemic heart disease, and stroke death compared to the euploid population (5).
74 Obesity in DS is a multifactorial disease mainly associated with high caloric diets, low
75 physical activity, higher serum leptin levels, decreased resting energy expenditure, and
76 other comorbidities such as sleep apnea, hyperinsulinemia, gait disorders, and
77 dyslipidemias (5) . Most of the features of DS are expected to be related to the
78 overexpression of the genes located on chromosome 21, particularly those of the Down
79 Syndrome Critical Region (DSCR), leading to imbalanced interactions with other disomic
80 genes (6). Accordingly, microRNA (miRNA) genes located on chromosome 21 could play
81 a role in the DS phenotype, mostly unknown (4).

82 miRNAs are small non-coding strands of RNA (18–25 nucleotides), which post-
83 transcriptionally regulate almost 60% of all gene expression via inhibition of translation or
84 direct mRNA target degradation. These regulatory RNAs often have tissue-specific
85 expression, are detectable in peripheral blood, and may act as endocrine effectors on target

86 cells. Human chromosome 21 has more than 400 genes, including five miRNAs (miR-99a,
87 Let-7c, miR-125b-2, miR-155, and miR-802) whose expression leads to haploinsufficiency
88 for their mRNA target (7). miRDB database analysis (<http://mirdb.org/index.html>) (8),
89 predicted that miR-99a is a potential interactor of 47 mRNA targets, Let-7c of 990, miR-
90 125b-2 of 585, miR-155 of 701, and miR-802 of 631. This led us to hypothesize that
91 dysregulation of these miRNAs may play a role in the cognitive dysfunction, congenital
92 heart defects, childhood leukemia, and early-onset Alzheimer's disease (AD) in individuals
93 with DS.

94 Among those miRNAs, we focused on Let-7c and miR-155, which are critically
95 related to neurodegeneration and play a crucial role in the DS pathogenesis of dementia (9,
96 10). AD is the most common form of dementia, and it is characterized by two hallmarks,
97 the amyloid plaques formed by A β peptide deposits and the neurofibrillary tangles caused
98 by hyperphosphorylation and accumulation of Tau protein (11). In DS individuals, the
99 increased risk of early-onset Alzheimer disease is related to the trisomic dosage of the
100 genes for amyloid precursor protein (APP) and β secretase 2 (BACE2), essential proteins
101 for A β peptide production (12). In addition, the extra copies of miR-155 and Let-7c may
102 contribute to AD, as miR-155 is related to NF-kB signaling and T cell activation and
103 infiltration in the hippocampal parenchyma of the brain with AD, contributing to
104 neuroinflammation (9). Also, miR-155 is co-expressed with hyperphosphorylated Tau (9,
105 12), and Let-7c overexpression leads to morphological as well as functional deficits,
106 including impaired neuronal morphologic development, synapse formation, and synaptic
107 strength, as well as a marked reduction of neuronal excitability (10, 13). This miRNA
108 dysregulation has also been linked to impaired mitochondrial function (14),

109 neurodegeneration (15), and neurodevelopmental disorders (10). while DS and AD have
110 been found to have robust associations to dyslipidemias, particularly low HDL-Col
111 concentration, common conditions in DS patients (16-19).

112 Therefore, in the present work, we focused on the study of the expression profiles of
113 miR-155 and Let-7c miRNAs in DS and determining their association with biochemical
114 alterations related to lipid metabolism.

115 **Materials and methods**

116 **Study design**

117 A cross-sectional study was performed with 50 participants with DS and 52 healthy
118 controls. Individuals were selected at Down Syndrome Health Fairs organized by the
119 Autonomous University of Sinaloa. The study followed the provisions of the Declaration of
120 Helsinki and Good Clinical Practice guidelines, and the local institutional review board
121 approved the protocol. The research project was reviewed and approved by the Research
122 Ethics Committee at the Medicine Faculty of Autonomous University of Sinaloa, which has
123 a national certification (CONBIOÉTICA-25-CEI-003-20181012) for its duties. Parents or
124 legal guardians of people with DS were informed before the evaluation and provided
125 written consent to undergo study procedures.

126 DS individuals and controls were each grouped in 20-year old or younger (Group A)
127 and 21-year-old or older (Group B), according to the growth standards for children with DS
128 by the Disease Control and Prevention Center (CDC).

129

130 **Patients**

131 The inclusion criteria for this study were age over eight years and a DS diagnosis by
132 clinical and genetic criteria. Sex and age-matched control participants were used as a
133 reference. Exclusion criteria were the presence of congenital heart disease not treated with
134 surgery, severe sensory impairment, leukemia, and diagnosis of diabetes mellitus or
135 metabolic syndrome.

136 **Anthropometric measurement**

137 Anthropometric measurements were carried out following the procedures of the
138 International Society for the Advancement of Kinanthropometry (ISAK) during patient
139 examinations. Bodyweight was measured on subjects wearing light clothes using an
140 electronic bascule (Tanita HS-302) and height using a stadiometer (SECA 213). Body mass
141 index (BMI) was calculated, and individuals were classified according to the BMI/Age
142 tables of the World Health Organization (WHO).

143

144 **Biochemical analysis**

145 After overnight fast blood samples were obtained from an antecubital vein. Blood
146 was collected into two non-additive tubes, which were incubated 30 min at room
147 temperature and spun at 3000 x g at 4°C for 10 min. Serum samples were collected and
148 stored at -80°C. Serum lipids (total cholesterol and HDL-cholesterol), triglycerides, and
149 plasma glucose were measured using commercial enzymatic kits (HUMAN Diagnostics
150 Worldwide; Wiesbaden, Germany). LDL-cholesterol was calculated using a modified
151 Friedewald equation (20). For the classification of biochemical parameters, we used the
152 cut-off points of the International Diabetes Federation (IDF) and the National Cholesterol
153 Education Program (NCEP) for children, adolescents, and adults (21, 22).

154

155 **RNA isolation**

156 Total miRNA purification was performed with the miRNeasy-serum/plasma
157 extraction kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. RNA

158 extracted was quantified using the NanoDrop 2000 spectrophotometer (Thermo Fisher
159 Scientific, MA, USA) measuring absorbance at 260 nm and 280 nm. Samples were eluted
160 with RNase-free water for subsequent cDNA synthesis and stored at -80°C.

161

162 **Reverse Transcription (RT)**

163 Total RNA was reverse transcribed using a miScript II RT Kit (Qiagen, Hilden,
164 Germany) in a StepOne Plus (Thermo Fisher Scientific, MA, USA) according to the
165 manufacturer's protocol.

166

167 **Real-Time PCR**

168 Quantification of Let-7c (Cat. No. 00003129), and miR-155 (Cat. No. 00031486),
169 mature miRNAs were determined using the miScript SYBR Green PCR kit (Qiagen,
170 Hilden, Germany) and SNORD68 (Cat. No. 00033712) as normalizer. PCR reactions were
171 each performed in a final volume of 15 µl in the StepOne Plus thermocycler. The Melting
172 Curve was performed to observe the specificity of reactions. Relative quantification was
173 obtained using the Pfaffl method, which describes the use of reaction efficiencies obtained
174 using LinReg PCR software (23).

175

176 **In silico prediction of miRNAs and their target genes**

177 For the prediction of miR-155 and Let-7c gene targets, miRDB
178 (<http://www.mirdb.org>) and TargetScan 7.2 (www.targetscan.org) public databases were
179 used (8, 24). To determine the biological processes under each miRNA regulation, we

180 performed network enrichment analysis using Metascape (25) (<http://metascape.org/>).
181 Then, we used the Meta-analysis workflow to compare miR155 and Let-7c targets and to
182 identify unique and shared biological pathways in which they are involved.

183

184 **Statistical analysis**

185 Statistical tests were performed using SPSS v.22. Data were examined for normality
186 based on skewness and kurtosis before analysis. Descriptive statistics of clinical
187 characteristics between groups were represented as means, \pm standard deviation. Mann-
188 Whitney U and Student's t-test were used to examine the statistical difference in clinical
189 parameters between healthy controls subjects and patients with DS. ANOVA Kruskal-
190 Wallis test for differences between group respect to miRNA expression was assessed.
191 Correlations between fold changes of miRNA levels and changes in biochemical
192 characteristics were determined by Pearson correlation coefficients. Statistical significance
193 was set at $p < 0.05$.

194

195 Results

196 Anthropometry and biochemical parameters

197 A total of 50 individuals with Down syndrome and 52 healthy controls from 8 to 52
198 years of age were characterized and divided into two groups: A (A Control and A DS) and
199 B (B Control and B DS). All individuals were matched by sex and age. The mean age was
200 10.9 ± 2.4 and 11.3 ± 2.7 years for A Control and A DS groups, respectively; and 28.3 ± 11 and
201 28.5 ± 11 years for B Control and B DS groups, respectively, with no significant difference
202 between them, which indicates homogeneity of age divided groups. For bodyweight, there
203 was no significant difference between A groups (Control, 41.4 ± 12.5 and DS, 37.9 ± 13.2
204 kg,) and B groups (Control, 63.3 ± 10.3 kg and DS, 64.3 ± 12.7 kg) (all results are presented
205 in this order heretofore). Nevertheless, we observed a significant difference in height
206 between A groups (1.45 ± 0.11 m and 1.3 ± 0.12 m, $p=0.001$), and B groups (1.6 ± 0.07 m and
207 1.5 ± 0.08 m, $p=0.001$). Moreover, a significant difference in BMI was found between B
208 groups (22.85 ± 2.61 and 28.79 ± 6.03 m/kg², $p=0.006$), while no difference was found
209 between A groups (Table 1). Altogether, these results indicate that the risk of overweight in
210 DS individuals is higher at older stages, in keeping with previous reports (5, 26).

211

212

213

214 **Table 1. Participant characteristics and biochemical parameters**

Clinical	Control A	DS A	<i>P</i> value	Control B	DS B	<i>P</i>
Characteristics						value

Age (years)	10.9±2.4	11.3±2.7	NS	28.3±11	28.5±11	NS
Body weight (kg)	41.4±12.5	37.9±13.2	NS	63.3±10.3	64.3±12.7	NS
Height (m)	1.45±0.11	1.3±0.12	.0001	1.6±0.07	1.5±0.08	.0001
BMI (kg/m ²)	19.2±3.3	20.5±4.3	NS	22.9±2.6	28.8±6.0	.006
Glucose (mg/dL)	86.4±11.1	87.4±10.4	NS	91.08±5.1	91±13.6	NS
Cholesterol (mg/dL)	118.7±30.2	181.2±44.6	.0001	157.4±60.6	171.7±54.2	NS
HDL (mg/dL)	56.8±15.4	46.7±13.17	.003	68.8±13.2	42.5±9.1	.0001
Triglycerides (mg/dL)	75.6±43.3	139.1±44.5	.0001	80.3±24.5	152.7±83.5	.011
LDL (mg/dL)	109.6±43.1	106.4±37.6	NS	72.8±55.1	115±28.07	.029

215 Data are presented as mean ± SD; NS, non-significative; BMI, body mass index; HDL,

216 High-density lipoprotein cholesterol; LDL, Low-density lipoprotein cholesterol.

217

218 Biochemical analysis revealed a significant difference between A groups in total
 219 cholesterol (118.7±30.2 and 81.2±44.65 mg/dL, $p=0.0001$), HDL (56.82±15.4 and
 220 46.7±13.17 mg/dL, $p=0.003$) and triglycerides (75.65±43.33 and 139.1±44.53 mg/dL, $p=$
 221 0.0001), but not for LDL and glucose levels. Similarly, for B groups we observed
 222 differences in HDL (68.8±13.2 and 42.5±9.1 mg/dL, $p=0.0001$), triglycerides (80.3±24.5
 223 and 152.7±83.5 mg/dL, $p=0.011$) and LDL (72.8±55.15 and 115±28.07 mg/dL, $p=0.029$),
 224 but not for total cholesterol and glucose (Table 1). Overall, these results show alterations in
 225 the parameters of lipid metabolism due to the genetic background of DS.

226

227 **Serum miRNAs expression**

228 Analysis by qRT-PCR of Let-7c expression revealed a 2.2-fold increase in DS
229 relative to the control group (Fig 1A). Moreover, when age was taken into account, in both
230 age groups, Let-7c expression was found to be higher in DS compared to their respective
231 control groups (DS A: 2.3-fold and DS B: 1.8-fold) (Fig 1A). Nevertheless, no differences
232 were detected for miR-155 in both analyses (Fig 1B).

233

234 **Fig 1. The miRNA Let-7c is up-regulated in DS but not miR-155.** Expression of
235 miRNAs Let-7 c (A) and miR-155 (B) was measured by qRT-PCR in DS people and
236 referenced to control individuals. For each miRNA, total and age-divided population were
237 done. Data are plotted as relative value for each individual, and means for each group
238 statistically analyzed by Mann-Whitney U test (*p<0.05, **p<0.01). DS: down syndrome;
239 Group A: ≤20 years old; Group B: ≥21 years old.

240

241 Furthermore, the association of miRNA expression with lipid serum levels was
242 analyzed. For Let-7c, overexpression of 1.7-fold and 2.9-fold was observed when analyzed
243 for Normal-HDL or Low-HDL DS group compared to the control group. These results
244 indicate that DS individuals with lower HDL levels express higher amounts of Let-7c. This
245 behavior was not observed when analyzed the other lipid parameters. A similar analysis
246 performed for miR-155 showed no significant changes (Table 2).

247

248 **Table 2. miRNAs quantification according to lipid concentration, in Down syndrome**
249 **groups**

miRNAs	DS Normal-HDL	DS Low-HDL	P-value
Let-7c	1.7	2.9	.0009
miR-155	1	1.9	NS

	DS Normal-TG	DS High-TG	
Let-7c	2.4	1.6	.0007
miR-155	1.4	1.2	NS

	DS Normal-Cholesterol	DS High-Cholesterol	
Let-7c	2.2	2.0	.02
miR-155	1.3	1.3	NS

	DS Normal-LDL	DS High-LDL	
Let-7c	2.3	1.8	.005
miR-155	1.3	1.3	NS

250 Data are presented as mean; NS, non-significative; TG, triglycerides; HDL, High-density
 251 lipoprotein cholesterol; LDL, Low-density lipoprotein cholesterol.

252 **Correlation between miRNAs expression and biochemical** 253 **parameters**

254 Since lipid concentrations have been linked to cognitive impairment, biochemical
 255 parameters measured in patients were correlated with expression values of miRNAs Let-7c
 256 and miR-155 (Table 3). No correlation was detected for Let-7c levels with any lipid or
 257 glucose parameter (Table 3). However, we observed a negative correlation between the

258 HDL levels and the increase in the expression of miR-155 ($p < 0.003$, $r = -0.421$) (Table 3).
259 Interestingly, an overall landscape showed that almost all of DS individuals have Let7-c
260 miRNA expression up-regulated, and miR-155 expression appears to be up-regulated when
261 HDL levels are far below normal (Tables 2 and 3).

262

263 **Table 3. Bivariate correlation of Let-7c and miR-155 levels with changes in clinical**
264 **characteristics**

	Let-7c		miR-155	
	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>
Glucose	-0.217	0.134	0.004	0.977
Triglycerides	-0.132	0.363	-0.181	0.211
Cholesterol	-0.061	0.675	-0.086	0.553
LDL-C	0.123	0.397	0.011	0.935
HDL-C	-0.217	0.133	-0.395	0.004

265 HDL, High-density lipoprotein cholesterol; LDL, Low-density lipoprotein cholesterol.

266

267 **Targets of miR-155 and Let-7c: unique and shared biological**
268 **pathways**

269 To gain insight into the targets of miR-155 and Let-7c in DS patients, an *in-silico*
270 analysis was performed to find biological pathways that could be differentially affected.
271 miR-155 and Let-7c targets were determined using the miRDB (<http://www.mirdb.org>) and
272 TargetScan 7.2 (www.targetscan.org) public databases. Clustering networks of the top 20
273 enriched GO: BP (Gene Ontology: Biological Processes) terms for miR-155 and Let-7c

274 targets are shown in Fig 2. *In silico* prediction, analysis showed that miR-155 has 701
275 mRNA targets, while Let-7c could be regulating 990 putative genes. Comparative analysis
276 of their targets showed that only 52 genes could be regulated by both miRNAs (Fig 3 and
277 S1 Fig). Despite the discrepancy in genetic regulation, both miRNAs are linked at the
278 biological pathway level (S1 Fig). It is noteworthy that enrichment analysis of biological
279 processes revealed that the highest p-value enriched GO: BP terms are unique pathways for
280 each miRNA (Figs 2 and 3).

281

282 **Fig 2. Networks of enriched ontology clusters for Let-7c (A) and miR-155 (B) miRNAs**
283 **regulated targets.** GO: BP, Gene Ontology: Biological Processes terms.

284 **Figure 3. Heatmap of GO: BP enriched terms across miR155 and Let-7c target genes**
285 **colored by p-values.** GO: BP, Gene Ontology: Biological Processes terms.

286

287

288 Bioinformatic analyses of Let-7c gene targets revealed enrichment of signaling
289 pathways associated with diseases, particularly to Type 2 diabetes, such as the AGE/RAGE
290 pathway and the carbohydrate derivate biosynthetic process (Fig 2A). A possible
291 mechanism of Let-7c genetic regulation, is the signaling cascade events of the IGF-1/IGF-
292 1R pathway, which induces the phosphorylation and inhibition of forkhead (FoxO)
293 transcription factors. The FoxO signaling pathway, which is highly enriched among Let-7
294 targets, is involved in the regulation of both survival and apoptotic genes by inducing the
295 synthesis of the ligand of the apoptosis stimulating fragment (FasL) and the death mediator
296 that interacts with BcL-2 (Bim) (Fig 2A). Overall, these results suggest an essential

297 function for Let-7 in cell survival and carbohydrate metabolism, which may be implicated
298 in the molecular etiology of neurodevelopmental disorders, such as DS.

299 Among miR-155 unique gene targets, a high enrichment was observed for a group
300 of homophilic adhesion proteins via plasma membrane adhesion composed mostly of
301 clustered alfa protocadherins (Pcdhs) and other nonclustered members (Fig 2B). miR-155 is
302 mainly related to inflammatory pathways such as interleukin signaling. Among the top 20
303 enriched GO: BP terms for miR-155, no associations with lipid metabolism pathways were
304 found. Searching for lipid-linked pathways, we identified from 100 enriched GO: BP terms
305 one related to long-chain fatty acid import (S2 Fig).

306 Discussion

307 The present study focused on the comparative analyses expression of the miRNAs
308 miR-155 and Let-7c in DS and euploid patients. These miRNAs, located in chromosome
309 21, have been implicated in neurodegeneration and also have a link to dyslipidemias, and
310 early-stage development of Alzheimer's pathogenesis.

311 To improve the therapeutic approach to DS comorbidities, it is necessary to
312 understand them from their molecular level to their clinical features. Consistently with this,
313 a higher difference in the height for DS group compared to the control group was observed.
314 Several reports have found similar differences highlighting short stature as a typical feature
315 in DS, and growth velocity being markedly reduced, mainly between the ages ranging from
316 six months to three years (27). Deficiencies in the secretion of growth hormone (GH)
317 which regulates the production of Insulin-like growth factor (IGFs) have been clearly
318 associated to the marked reduction in speed of growth in young children with DS (28, 29),
319 and consistently with those findings, it has been demonstrated that this phenotype can be
320 normalized with GH therapy (30, 31).

321 We also observed that BMI was higher in DS compared to the control in the older
322 group analyzed (B groups), while no differences were observed between the younger
323 groups (A control and A DS groups). Previous studies in children and adolescents revealed
324 that children with DS have a healthy BMI, maybe due to parental control in their diet (32).
325 During adulthood, however, there is greater independence of DS individuals for choosing
326 their food, which tends to have a higher caloric content (33). Moreover, risk factors
327 associated with the development of obesity have been described in individuals with DS,

328 such as a decrease in basal metabolism compared to those without DS (34, 35).
329 Additionally, individuals with DS have muscular hypotonia, a phenotype characterized by
330 difficulty in performing activities that involve physical attrition, contributing to a sedentary
331 lifestyle, and, consequently, to weight gain (36, 37).

332 In addition to dyslipidemias, alterations in the expression of miRNAs could
333 represent other possible risk factors for impaired cognition and a possible link with the
334 early age onset of AD. miRNAs can mobilize through the bloodstream. Therefore, they can
335 be studied by non-invasive methods. The miRNAs Let-7c and miR-155, both present on
336 chromosome 21, were selected for their importance in phenotype variability generating
337 haploinsufficiency of target genes, and their possible relation with the development of
338 Alzheimer's disease in patients with DS, even at early ages.

339 We do not observe significant changes for miR-155 expression in peripheral blood
340 from DS people. Previous studies using postmortem brain tissue of 34-42-year-old donors
341 with DS and dementia found the significant up-regulation of miR-155 (9) . Interestingly,
342 in the DS mouse model Ts65Dn, miR-155 showed significant overexpression in the
343 hippocampus and the whole blood, but not in lung tissue. Also, there was a down-
344 regulation of the mRNA target Ship1(inositol phosphatase) in the Ts65Dn hippocampus,
345 but not in lung tissue (38). The previous evidence and our results suggest that
346 physiopathological changes in miR-155 expression may be tissue and temporally specific,
347 and it is necessary for an in-depth follow-up study of these changes in the brain tissue to
348 understand its contribution to neurodegeneration in DS.

349 In murine and cellular models, the role in the development and central nervous
350 system (CNS) functions of several miR-155 gene targets have been demonstrated (9, 39).

351 miR-155 predicted gene target pathways are highly enriched for adhesion molecules such
352 as Pcdhs, which are type I transmembrane receptors expressed predominantly in the central
353 nervous system (CNS) and located in part in synapses involved in pivotal developmental
354 processes, such as axon guidance and dendrite arborization. Changes in their expression
355 might play a role in DS, as has been demonstrated for other neurodevelopmental disorders
356 such as autism, encephalopathy epilepsy, Fragile X syndrome and neurodegenerative
357 diseases (40-42). Ultimately, our results showed a negatively correlation between miR-155
358 expression and HDL-cholesterol. Although there are not reports for miR-155 mRNA targets
359 involved in lipid metabolism, a deeper *in silico* analysis showed that it may modulate
360 molecules such as fatty acid-binding protein (FABP), which has been used as a cardiac
361 marker because of its function as a long-chain fatty acid carrier in blood and its important
362 role in lipid metabolism (43). Altogether, these observations reinforce its possible role in
363 the development of dementia observed in DS.

364 Regarding *Let-7c* expression, the results obtained are consistent with other studies
365 that found a two-fold expression increase in the DS group compared to the euploid
366 population (9, 44). It is also well known that *Let-7c* is involved in mechanisms related to
367 neurological alterations as an activator of TLR7, in both immune cells and neurons,
368 damaging the CNS through the production of proinflammatory molecules such as the tumor
369 necrosis factor α (TNF α); and the activation of apoptosis via caspases 3, inducing
370 neurodegeneration and neuronal cell death (15). The overexpression of *Let-7c* into neurons
371 led to morphological and synaptic alterations, and a marked reduction in neuronal
372 excitability through the inhibition of MeCP2 (10), and decreased the expression of the IGF-
373 1R, which is expressed differentially throughout the brain (45). Furthermore, IGF-

374 IR/Insulin alterations are characteristic in patients with AD, Parkinson's, and other
375 neurodegenerative disorders. IGF-1 is an essential factor for healthy growth and
376 development, involved in neuronal survival, myelin synthesis, cell metabolism, astrocyte
377 function, angiogenesis, neuronal excitability, and oligodendrogenesis (46). A decrease in
378 IGF-1 has also been reported in people with DS (29, 47, 48). Moreover, the overexpression
379 of Let-7c in the brain tissue of DS adults with dementia was observed, demonstrating its
380 involvement with this process (9). Let-7c overexpression is also related to mitochondrial
381 cardiomyopathies. In trisomic hearts, down-regulation was observed of the
382 SLC25A4/ANT1 gene (Solute carrier family 25 member 4/ Adenine nucleotide translocator
383 1), a predicted target of Let-7c and associated to mitochondrial and cardiac anomalies (14).
384 Also, mitochondrial dysfunction is closely linked to the increase in oxidative stress, which
385 has a central role in the pathogenesis of DS and the etiology of different intellectual
386 disabilities, as it affects highly oxidative tissues such as the brain, suggesting a synergism
387 between Let-7c and oxidative stress (49-52).

388 Integrating alterations in miRNA expression with dyslipidemias for the
389 physiopathology in DS neurodegeneration, we start from the evidence that indicates
390 dyslipidemias are a risk factor for the development of dementias such as Alzheimer's (53-
391 55). Elevated cholesterol levels induce accelerated APP processing in its amyloidogenic
392 pathway, a condition related to the development of Alzheimer's dementia (56-59). Studies
393 of the lipid profile in children with DS, compared with their euploid siblings, adjusting for
394 BMI showed that even in normal body weight, the DS children presented alterations in
395 cholesterol, triglycerides, HDL, and LDL (16, 19). The results obtained in this study
396 demonstrate that individuals with DS have alterations in the lipid profile compared to

397 controls at an early age as an increase in cholesterol, triglycerides and low levels of HDL;
398 and consistent in adults with DS. These results support the idea that the alterations in lipid
399 metabolism are not only due to obesity, but possibly the presence of an extra copy of
400 chromosome 21; meaning a risk factor for AD neurodegeneration. Several reports have
401 determined a positive correlation of A β levels with elevated cholesterol and low HDL
402 levels (55, 60, 61). HDL maintains the transport of cholesterol to neurons for functioning
403 and has a role in A β clearance; hence, high cholesterol levels and low HDL levels are
404 related to cognitive disorders (55, 60-62). In line with this evidence, we found that Let-7c
405 overexpression was higher among DS individuals with low-HDL levels and that miR-155
406 levels negatively correlate to low HDL levels. Even though not mRNA targets for miR-155
407 and Let-7c involved in lipid metabolism have been demonstrated, and based on the *in-silico*
408 analysis, a direct relationship between their expression and alterations in the lipid profile
409 cannot be discarded. However, the fact that there is a negative correlation of their
410 expression with the concentration of HDL or a differential expression according to lipid
411 levels suggests the existence of a molecular network linking both parameters.

412 Overall, these results suggest that a set of differentially expressed miRNAs
413 promotes the progression of cognitive impairment in patients with DS by regulating genes
414 of biological pathways involved in lipid metabolism and nervous system development.
415 Moreover, other biological processes such as inflammation and the immune system must
416 integrate for Alzheimer's neurodegeneration in the DS puzzle.

417

418

419 **Conclusion**

420 Altogether, our results reveal a pattern of miR-155 and Let-7c miRNAs expression
421 that correlates with the alteration in the concentration of HDL, reinforcing the hypothesis of
422 the participation of this lipoprotein in the homeostasis of molecules related to cognitive
423 function and early development of dementias, a frequent feature in Down syndrome. The
424 data suggests that in Down syndrome, Let-7c and miR-155, located on the triplicated
425 chromosome 21, maybe dysregulated and playing a key role in the pathogenesis of
426 Alzheimer´s dementia. This implies that modulating the expression of these miRNAs in the
427 CNS may help abrogate the inevitable pathway to dementia in adults with Down syndrome.

428 **Acknowledgments**

429 Carla Angulo-Rojo and Javier Magaña Gómez received financial support from Universidad
430 Autónoma de Sinaloa (PROFAPI2014/015 and PROFAPI2015/015). Jesús Manuel Pérez-
431 Villareal received a Master fellowship from CONACyT (CVU785590). Katia Aviña-
432 Padilla received a postdoctoral fellowship from DGAPA-UNAM and acknowledges
433 CABANA program for training in bioinformatics. Technical support for this work was
434 obtained from Luis Alberto Aguilar Bautista, Alejandro de León Cuevas, Carlos Sair Flores
435 Bautista and Jair García of the Laboratorio Nacional de Visualización Científica Avanzada
436 (LAVIS).
437

438 **References**

- 439 1. de Graaf G, Buckley F and Skotko BG: Estimation of the number of people with
440 Down syndrome in the United States. *Genet Med* 19: 439-447, 2017.
- 441 2. Sierra Romero MDC, Navarrete Hernandez E, Canun Serrano S, Reyes Pablo AE
442 and Valdes Hernandez J: [Prevalence of Down syndrome using certificates of live births
443 and fetal deaths in Mexico 2008-2011]. *Bol Med Hosp Infant Mex* 71: 292-297, 2014.
- 444 3. Saghazadeh A, Mahmoudi M, Dehghani Ashkezari A, Oliaie Rezaie N and Rezaei
445 N: Systematic review and meta-analysis shows a specific micronutrient profile in people
446 with Down Syndrome: Lower blood calcium, selenium and zinc, higher red blood cell
447 copper and zinc, and higher salivary calcium and sodium. *PLoS One* 12: e0175437, 2017.
- 448 4. Antonarakis SE: Down syndrome and the complexity of genome dosage imbalance.
449 *Nat Rev Genet* 18: 147-163, 2017.
- 450 5. Bertapelli F, Pitetti K, Agiovlasis S and Guerra-Junior G: Overweight and obesity
451 in children and adolescents with Down syndrome-prevalence, determinants, consequences,
452 and interventions: A literature review. *Res Dev Disabil* 57: 181-192, 2016.
- 453 6. Asim A, Kumar A, Muthuswamy S, Jain S and Agarwal S: "Down syndrome: an
454 insight of the disease". *J Biomed Sci* 22: 41, 2015.
- 455 7. Elton TS, Sansom SE and Martin MM: Trisomy-21 gene dosage over-expression of
456 miRNAs results in the haploinsufficiency of specific target proteins. *RNA Biol* 7: 540-547,
457 2010.
- 458 8. Chen Y and Wang X: miRDB: an online database for prediction of functional
459 microRNA targets. *Nucleic Acids Res* 48: D127-D131, 2019.

- 460 9. Tili E, Mezache L, Michaille JJ, *et al*: microRNA 155 up regulation in the CNS is
461 strongly correlated to Down's syndrome dementia. *Ann Diagn Pathol* 34: 103-109, 2018.
- 462 10. McGowan H, Mirabella VR, Hamod A, *et al*: hsa-let-7c miRNA regulates synaptic
463 and neuronal function in human neurons. *Front Synaptic Neurosci* 10: 19, 2018.
- 464 11. Scheltens P, Blennow K, Breteler MM, *et al*: Alzheimer's disease. *Lancet* 388: 505-
465 517, 2016.
- 466 12. Ballard C, Mobley W, Hardy J, Williams G and Corbett A: Dementia in Down's
467 syndrome. *Lancet Neurol* 15: 622-636, 2016.
- 468 13. Chen J, Qi Y, Liu CF, Lu JM, Shi J and Shi Y: MicroRNA expression data analysis
469 to identify key miRNAs associated with Alzheimer's disease. *J Gene Med* 20: e3014, 2018.
- 470 14. Izzo A, Manco R, de Cristofaro T, *et al*: Overexpression of chromosome 21
471 miRNAs may affect mitochondrial function in the hearts of Down syndrome fetuses. *Int J*
472 *Genomics* 2017: 8737649, 2017.
- 473 15. Lehmann SM, Kruger C, Park B, *et al*: An unconventional role for miRNA: let-7
474 activates Toll-like receptor 7 and causes neurodegeneration. *Nat Neurosci* 15: 827-835,
475 2012.
- 476 16. de la Piedra MJ, Alberti G, Cerda J, Cárdenas A, Paul MA and Lizama M: Alta
477 frecuencia de dislipidemias en niños y adolescentes con Síndrome de Down. *Rev Chil*
478 *Pediatr* 88: 595-601, 2017.
- 479 17. Tenneti N, Dayal D, Sharda S, *et al*: Concentrations of leptin, adiponectin and other
480 metabolic parameters in non-obese children with Down syndrome. *J Pediatr Endocrinol*
481 *Metab* 30: 831-837, 2017.

- 482 18. Buonomo PS, Bartuli A, Mastrogiorgio G, *et al*: Lipid profiles in a large cohort of
483 Italian children with Down syndrome. *Eur J Med Genet* 59: 392-395, 2016.
- 484 19. Adelekan T, Magge S, Shults J, Stallings V and Stettler N: Lipid profiles of children
485 with Down syndrome compared with their siblings. *Pediatrics* 129: e1382-1387, 2012.
- 486 20. Friedewald WT, Levy RI and Fredrickson DS: Estimation of the concentration of
487 low-density lipoprotein cholesterol in plasma, without use of the preparative
488 ultracentrifuge. *Clin Chem* 18: 499-502, 1972.
- 489 21. NIH and NHLBI: ATP III Guidelines at-a-glance quick desk reference. *Journal* 10,
490 2001.
- 491 22. Zimmet P, Alberti KGM, Kaufman F, *et al*: The metabolic syndrome in children
492 and adolescents—an IDF consensus report. *Pediatr Diabetes* 8: 299-306, 2007.
- 493 23. Ruijter JM, Ramakers C, Hoogaars WM, *et al*: Amplification efficiency: linking
494 baseline and bias in the analysis of quantitative PCR data. *Nucleic Acids Res* 37: e45,
495 2009.
- 496 24. Agarwal V, Bell GW, Nam J-W and Bartel DP: Predicting effective microRNA
497 target sites in mammalian mRNAs. *eLife* 4: e05005, 2015.
- 498 25. Zhou Y, Zhou B, Pache L, *et al*: Metascape provides a biologist-oriented resource
499 for the analysis of systems-level datasets. *Nat Commun* 10: 1523, 2019.
- 500 26. Basil JS, Santoro SL, Martin LJ, Healy KW, Chini BA and Saal HM: Retrospective
501 study of obesity in children with Down syndrome. *J Pediatr* 173: 143-148, 2016.
- 502 27. Anneren G, Gustafsson J, Sara V and Tuvemo T: Normalized growth velocity in
503 children with Down's syndrome during growth hormone therapy. *J Intellect Disabil Res* 37:
504 381-387, 1993.

- 505 28. Castells S, Torrado C, Bastian W and Wisniewski K: Growth hormone deficiency in
506 Down's syndrome children. *J Intellect Disabil Res* 36: 29-43, 1992.
- 507 29. Anneren G, Gustavson KH, Sara VR and Tuvemo T: Growth retardation in Down
508 syndrome in relation to insulin-like growth factors and growth hormone. *Am J Med Genet*
509 *Suppl* 7: 59-62, 1990.
- 510 30. Anneren G, Tuvemo T, Carlsson-Skwirut C, *et al*: Growth hormone treatment in
511 young children with Down's syndrome: effects on growth and psychomotor development.
512 *Arch Dis Child* 80: 334-338, 1999.
- 513 31. Meguri K, Inoue M, Narahara K, *et al*: Therapeutic efficacy and safety of GH in
514 Japanese children with Down syndrome short stature accompanied by GH deficiency. *Clin*
515 *Pediatr Endocrinol* 22: 65-72, 2013.
- 516 32. Melville CA, Cooper S-A, McGrother CW, Thorp CF and Collacott R: Obesity in
517 adults with Down syndrome: a case-control study. *J Intellect Disabil Res* 49: 125-133,
518 2005.
- 519 33. Grammatikopoulou MG, Manai A, Tsigga M, Tsiligioglou-Fachantidou A, Galli-
520 Tsinopoulou A and Zakas A: Nutrient intake and anthropometry in children and adolescents
521 with Down syndrome--a preliminary study. *Dev Neurorehabil* 11: 260-267, 2008.
- 522 34. Allison DB, Gomez JE, Heshka S, *et al*: Decreased resting metabolic rate among
523 persons with Down Syndrome. *Int J Obes Relat Metab Disord* 19: 858-861, 1995.
- 524 35. Luke A, Roizen NJ, Sutton M and Schoeller DA: Energy expenditure in children
525 with Down syndrome: correcting metabolic rate for movement. *J Pediatr* 125: 829-838,
526 1994.

- 527 36. Shahabi NS, Fakhraee H, Kazemian M, *et al*: Frequency and causes of hypotonia in
528 neonatal period with the gestational age of more than 36 Weeks in NICU of Mofid Children
529 Hospital, Tehran, Iran during 2012-2014. *Iran J Child Neurol* 11: 43-49, 2017.
- 530 37. Korenberg JR, Chen XN, Schipper R, *et al*: Down syndrome phenotypes: the
531 consequences of chromosomal imbalance. *Proc Natl Acad Sci U S A* 91: 4997-5001, 1994.
- 532 38. Bofill-De Ros X, Santos M, Vila-Casadesus M, *et al*: Genome-wide miR-155 and
533 miR-802 target gene identification in the hippocampus of Ts65Dn Down syndrome mouse
534 model by miRNA sponges. *BMC Genomics* 16: 907, 2015.
- 535 39. Keck-Wherley J, Grover D, Bhattacharyya S, *et al*: Abnormal microRNA
536 expression in Ts65Dn hippocampus and whole blood: contributions to Down syndrome
537 phenotypes. *Dev Neurosci* 33: 451-467, 2011.
- 538 40. Kim S-Y, Yasuda S, Tanaka H, Yamagata K and Kim H: Non-clustered
539 protocadherin. *Cell Adh Migr* 5: 97-105, 2011.
- 540 41. Keeler AB, Molumby MJ and Weiner JA: Protocadherins branch out: Multiple roles
541 in dendrite development. *Cell Adh Migr* 9: 214-226, 2015.
- 542 42. Yan X, Lukas J, Lin J, *et al*: Aberrant expressions of delta-protocadherins in the
543 brain of *Npc1* mutant mice. *Histol Histopathol* 29: 1185-1199, 2014.
- 544 43. French D and Wu AHB: Chapter 9.12 - Cardiac Markers. In: *The Immunoassay*
545 *Handbook* (Fourth Edition). Wild D (ed). Elsevier, Oxford, pp817-831, 2013.
- 546 44. Xu Y, Li W, Liu X, *et al*: Identification of dysregulated microRNAs in lymphocytes
547 from children with Down syndrome. *Gene* 530: 278-286, 2013.

- 548 45. Liu GX, Ma S, Li Y, *et al*: Hsa-let-7c controls the committed differentiation of IGF-
549 1-treated mesenchymal stem cells derived from dental pulps by targeting IGF-1R via the
550 MAPK pathways. *Exp Mol Med* 50: 25, 2018.
- 551 46. Bassil F, Fernagut P-O, Bezard E and Meissner WG: Insulin, IGF-1 and GLP-1
552 signaling in neurodegenerative disorders: targets for disease modification? *Prog Neurobiol*
553 118: 1-18, 2014.
- 554 47. Barreca A, Rasore Quartino A, Acutis MS, *et al*: Assessment of growth hormone
555 insulin like growth factor-I axis in Down's syndrome. *J Endocrinol Invest* 17: 431-436,
556 1994.
- 557 48. Torrado C, Bastian W, Wisniewski KE and Castells S: Treatment of children with
558 Down syndrome and growth retardation with recombinant human growth hormone. *J*
559 *Pediatr* 119: 478-483, 1991.
- 560 49. Esbensen AJ: Health conditions associated with aging and end of life of adults with
561 Down syndrome. *Int Rev Res Ment Retard* 39: 107-126, 2010.
- 562 50. Perluigi M and Butterfield DA: Oxidative stress and Down syndrome: a route
563 toward Alzheimer-like dementia. *Curr Gerontol Geriatr Res* 2012: 724904, 2012.
- 564 51. Valenti D, de Bari L, De Filippis B, Henrion-Caude A and Vacca RA:
565 Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: an
566 overview of Down syndrome, autism, Fragile X and Rett syndrome. *Neurosci Biobehav*
567 *Rev* 46 Pt 2: 202-217, 2014.
- 568 52. Wallace DC and Fan W: Energetics, epigenetics, mitochondrial genetics.
569 *Mitochondrion* 10: 12-31, 2010.

- 570 53. Real de Asua D, Parra P, Costa R, Moldenhauer F and Suarez C: Evaluation of the
571 impact of abdominal obesity on glucose and lipid metabolism disorders in adults with
572 Down syndrome. *Res Dev Disabil* 35: 2942-2949, 2014.
- 573 54. Mahley RW: Central nervous system lipoproteins: ApoE and regulation of
574 cholesterol metabolism. *Arterioscler Thromb Vasc Biol* 36: 1305-1315, 2016.
- 575 55. Tokuda T, Calero M, Matsubara E, *et al*: Lipidation of apolipoprotein E influences
576 its isoform-specific interaction with Alzheimer's amyloid β peptides. *Biochemical Journal*
577 348: 359-365, 2000.
- 578 56. Bodovitz S and Klein WL: Cholesterol modulates-secretase cleavage of amyloid
579 precursor protein. *J Biol Chem* 271: 4436-4440, 1996.
- 580 57. Burns M, Gaynor K, Olm V, *et al*: Presenilin redistribution associated with aberrant
581 cholesterol transport enhances β -amyloid production in vivo. *J Neurosci* 23: 5645-5649,
582 2003.
- 583 58. Buxbaum JD, Geoghagen NS and Friedhoff LT: Cholesterol depletion with
584 physiological concentrations of a statin decreases the formation of the Alzheimer amyloid
585 A β peptide. *J Alzheimers Dis* 3: 221-229, 2001.
- 586 59. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG and Simons K:
587 Cholesterol depletion inhibits the generation of β -amyloid in hippocampal neurons. *Proc*
588 *Natl Acad Sci U S A* 95: 6460-6464, 1998.
- 589 60. Ehehalt R, Keller P, Haass C, Thiele C and Simons K: Amyloidogenic processing of
590 the Alzheimer β -amyloid precursor protein depends on lipid rafts. *J Cell Biol* 160: 113-123,
591 2003.

592 61. Wahrle SE, Jiang H, Parsadanian M, *et al*: ABCA1 is required for normal central
593 nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. *J Biol Chem*
594 279: 40987-40993, 2004.

595 62. He Q, Li Q, Zhao J, *et al*: Relationship between plasma lipids and mild cognitive
596 impairment in the elderly Chinese: a case-control study. *Lipids Health Dis* 15: 146, 2016.

597

598 **Supporting information**

599 **S1 Fig. Circos graphs of overlapping and divergent targets genes of miRNA 155 and**

600 **Let-7c.** A) only at the gene level, purple curves link identical genes; B) including the

601 shared term level, blue curves link genes that belong to the same enriched ontology term

602 between the targets of both miRNAs. The inner circle represents gene lists, where hits are



603 arranged along the arc. Genes that hit multiple lists are colored in dark orange, and genes

604 unique to a list are shown in light orange.



605 **S2 Fig. Networks of enriched ontology clusters for miR-155 miRNA regulated targets.**

606 100 GO: BP, Gene Ontology: Biological Processes terms.


A)



B)




B)



- AGE-RAGE signaling pathway in diabetic complications
- production of miRNAs involved in gene silencing by RNA
- FoxO signaling pathway
- regulation of GTPase activity
- regulation of protein serine/threonine kinase activity
- embryo development ending in birth or egg hatching
- negative regulation of cell differentiation
- PI3K-Akt signaling pathway
- MAPK signaling pathway
- carbohydrate derivative biosynthetic process
- regulation of cell morphogenesis
- regulation of growth
- Pathways in cancer
- O-linked glycosylation
- Type II diabetes mellitus
- Transcriptional misregulation in cancer
- cellular response to nitrogen compound
- regulation of cell adhesion
- PID SHP2 PATHWAY
- ST JNK MAPK PATHWAY

created by
<http://metascape.org>

A)



- homophilic cell adhesion via plasma membrane adhesion molecules
- PID IL4 2PATHWAY
- Signaling by Interleukins
- Pathways in cancer
- muscle structure development
- PID BETA CATENIN NUC PATHWAY
- MAPK signaling pathway
- apoptotic signaling pathway
- regulation of DNA-binding transcription factor activity
- covalent chromatin modification
- proteolysis involved in cellular protein catabolic process
- regulation of protein kinase activity
- response to nerve growth factor
- leukocyte differentiation
- Oncogenic MAPK signaling
- vasculature development
- response to gamma radiation
- negative regulation of cell differentiation
- negative regulation of phosphate metabolic process
- PID ERBB1 DOWNSTREAM PATHWAY

created by
<http://metascape.org>

